-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, "The Lancet-Oncology" published a double-blind, randomized, placebo-controlled phase 3 clinical trial of olaparib as maintenance treatment for patients with BRCA1/2 mutant platinum-sensitive recurrent ovarian cancer (SOLO2/ENGOT-Ov21) final analysis result.
Olapali is a "first-in-class" PARP inhibitor jointly developed by AstraZeneca and MSD.
Olapali can treat a variety of cancers carrying germline BRCA mutations, mainly relying on the important principle of "synthetic lethality" in cancer treatment, which means that when the two signal pathways of cancer cells are inhibited, it will cause cell death.
This time, published in The Lancet-Oncology is a phase 3 clinical trial called SOLO2 (ENGOT-Ov21), which aims to evaluate olaparib monotherapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer Efficacy.
The median follow-up time was 65.
The researchers said that compared with placebo, olaparib can prolong the median overall survival by 12.
Reference materials:
[1]Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
